Karyopharm announces planned Ayrmid merger and Chapter 11 process
Karyopharm entered into a Restructuring Support Agreement providing for a merger between Ayrmid Ltd., the lead bidder in a court-supervised sale process, and a reorganized Karyopharm, and filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas. The process permits other parties to submit competing proposals and bids, and the transaction is expected to close in the first quarter of 2027 subject to conditions in the Chapter 11 plan. Karyopharm secured commitments for up...
Read source-backed brief